Last reviewed · How we verify
HOPE
HOPE, marketed by Eisai Inc., is a small molecule with a specific mechanism of action, though its primary indication and revenue figures are not specified. The drug's key strength lies in its patented composition, which is protected until 2028, providing a significant barrier to generic competition. The primary risk is the lack of detailed clinical trial results and competitor information, which could impact its market position and strategic planning.
At a glance
| Generic name | HOPE |
|---|---|
| Also known as | E7080 |
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Revealing Protective Immunity to Influenza Using Systems Immunology (PHASE4)
- Single Session Intervention to Promote Hope (NA)
- Mindfulness-Based Psychoeducation for Women With Gynecological Cancer (NA)
- HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients (PHASE3)
- Effect of Using a Reminder to Encourage Patients to be Active During Their Hospital Stay. (NA)
- Family-Supported Palliative Care in Advanced Lung Cancer (NA)
- VR for Hope: A Brief VR Self-help Protocol to Enhance Hope and Well-being in Young Adults (NA)
- HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HOPE CI brief — competitive landscape report
- HOPE updates RSS · CI watch RSS
- Eisai Inc. portfolio CI